RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Oladapo Bakare to Xenograft Model Antitumor Assays

Back to Details
This is a "connection" page, showing publications Oladapo Bakare has written about Xenograft Model Antitumor Assays.
Oladapo Bakare
Connection Strength
0.056
Xenograft Model Antitumor Assays
  1. Adekiya TA, Hudson T, Bakare O, Ameyaw EE, Adebayo A, Olajubutu O, Adesina SK. PSMA-targeted combination brusatol and docetaxel nanotherapeutics for the treatment of prostate cancer. Biomed Pharmacother. 2024 Aug; 177:117125.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support